Moderna, Inc. (NASDAQ:MRNA) Stock Position Trimmed by PFG Investments LLC

PFG Investments LLC decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 7.3% in the 2nd quarter, Holdings Channel.com reports. The firm owned 3,193 shares of the company’s stock after selling 252 shares during the period. PFG Investments LLC’s holdings in Moderna were worth $379,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC bought a new position in Moderna in the 2nd quarter worth approximately $26,000. Quest Partners LLC boosted its position in Moderna by 12,118.2% during the 2nd quarter. Quest Partners LLC now owns 1,344 shares of the company’s stock worth $160,000 after acquiring an additional 1,333 shares during the period. Varma Mutual Pension Insurance Co bought a new position in shares of Moderna in the second quarter worth $7,950,000. Ausdal Financial Partners Inc. acquired a new position in shares of Moderna during the second quarter valued at $234,000. Finally, Caprock Group LLC raised its stake in shares of Moderna by 66.2% during the second quarter. Caprock Group LLC now owns 5,122 shares of the company’s stock valued at $608,000 after purchasing an additional 2,040 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the subject of a number of recent analyst reports. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price for the company in a research report on Wednesday, August 28th. Evercore ISI reiterated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a report on Thursday, June 27th. Hsbc Global Res raised Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and lowered their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Ten investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $123.79.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the sale, the president now owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the completion of the sale, the president now directly owns 1,457,089 shares in the company, valued at $201,311,416.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. In the last three months, insiders have sold 108,158 shares of company stock worth $13,239,712. Corporate insiders own 15.70% of the company’s stock.

Moderna Trading Down 12.4 %

Shares of MRNA opened at $69.68 on Friday. The business’s 50-day moving average price is $96.06 and its 200 day moving average price is $111.86. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $26.78 billion, a P/E ratio of -4.45 and a beta of 1.68. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same period last year, the firm posted ($3.62) earnings per share. The firm’s quarterly revenue was down 29.9% compared to the same quarter last year. Analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.